ClinicalTrials.gg
RecruitingNCT06246799Updated Mar 10, 2026

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

A Phase 3 interventional study of Tirzepatide and Pioglitazone in Type 2 Diabetes (Adult Onset), sponsored by The University of Texas Health Science Center at San Antonio. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by The University of Texas Health Science Center at San Antonio · Phase 3, Interventional, and Other

How we know · 7 judgments

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 — 7 open to participants now, 12 under way, 2 of them phase 3. Tirzepatide · Diabetes Mellitus, Type 2.

Planned enrollment
19th of 43
256 · median 160
Started
2024
with 5 others
Phase 3
17 of 43
1 open now
Primary completion
2029-04
later than 11 of 11 live
Registered
31st of 43
by date

Among the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, this one is the 19th largest by planned enrollment, is one of 6 that started in 2024, is one of 17 in phase 3, reaches primary completion later than 11 of the 11 other live ones, and was the 31st registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 43 studies testing tirzepatide in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tirzepatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the efficacy, durability, and mechanism of HbA1c reduction produced by the combination of pioglitazone plus tirzepatide compared to metformin plus sitagliptin in patients with recently diagnosed type 2 diabetes mellitus.

Read the detailed description

This is a randomized open label controlled 2 arm study (with one of the arms containing 3 sub-groups) which aims to examine the effectiveness and long term effects on HbA1c reduction produced by the combination of pioglitazone plus tirzepatide versus metformin plus sitagliptin in recently diagnosed type 2 diabetes mellitus (T2DM) patients.

A subgroup of patients from group 1 will be invited to participate in a sub-study which lasts for 6 months and aims at exploring the metabolic/molecular mechanisms responsible for the study results. The selection of subjects to each subgroup will be done randomly and the end of sub-study, subjects will continue therapy and follow-up from month 6 on in the main study.

03

Conditions studied

  • Type 2 Diabetes (Adult Onset)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability of subject to understand and the willingness to sign a written document.
  2. Males and females; Age 18-75 years
  3. Recently (within 5 years) diagnosed Type 2 Diabetes Mellitus (T2DM) patients
  4. Drug naïve or receiving metformin monotherapy
  5. >6.5% (no limit on upper HbA1c value);
  6. Willingness to adhere to the product regimen
  7. Good general health
  8. Stable body weight over the preceding 3 months
  9. Agreement to adhere to Lifestyle Considerations throughout study duration.

Exclusion criteria

Exclusion Criteria:

  1. positive anti-GAD (antibodies to glutamic acid decarboxylase)
  2. pregnancy or plan of becoming pregnant
  3. evidence of proliferative diabetic retinopathy,
  4. plasma creatinine >1.4 females or >1.5 males;
  5. presence of congestive heart failure (CHF);
  6. history of cancer (\<5 years);
  7. prior history of pancreatitis,
  8. bladder cancer or family history of thyroid tumors;
  9. presence of hematuria in the urine analysis.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
256 participants (estimated)

Study arms

  • Experimental
    Group IC

    Tirzepatide starting at 2.5mg weekly titrated to 15mg weekly (2.5 month 1, 5mg month 2, 10mg month 3 and 15mg at month 4) with Pioglitazone beginning at 15mg daily and ending at 45mg daily (15mg month 1, 30mg month 2 and 45mg at month 3 onwards).

    Drug: Tirzepatide · Drug: Pioglitazone

  • Active comparator
    Group II

    Metformin starting at 1000mg XR daily and Sitagliptin 100mg daily at week 4, Metformin will be increased to 200mg.

    Drug: Sitagliptin · Drug: Metformin HCI XR

  • Active comparator
    Group IA

    Tirzepatide will be started at 2.5mg and increased to 15mg by month 4. At month 6, Pioglitazone will be added to the Tirzepatide, 15 mg daily.

    Drug: Tirzepatide · Drug: Pioglitazone

  • Active comparator
    Group 1B

    Pioglitazone will be started at 15mg and increased to 45 mg by month 3. At month 6, tirzepatide 2.5mg will be started and increased weekly as tolerated.

    Drug: Tirzepatide · Drug: Pioglitazone

Interventions

  • Tirzepatide:Participants will be initiated on 2.5mg weekly and increase their dose to 5mg at week 4, 10mg at week 8 and 15mg at week 12 as tolerated.

    Also known as: Mounjaro

  • Pioglitazone: Participants will begin therapy at 15mg daily for the first 4 weeks then increase dose to 30mg at week 4 and to 45 mg at week 8, as tolerated.

    Also known as: Actos

  • Sitagliptin: will be administered as a 100mg dose once daily.

    Also known as: Januvia

  • DrugMetformin HCI XR

    Metformin will be administered at a dose of 1000mg for the first 4 weeks and then the dose increased to 2000mg.

    Also known as: Extended Release Metformin

06

What researchers measure

Primary outcomes

  1. number of subjects achieving HbA1c <6.5% at 6 months (Efficacy)

    Therapy failure will be determined as HbA1c \>6.5% in two consecutive HbA1c measurements 3 months apart. Time to cumulative incidence of therapy failure curves will be created in subjects receiving pioglitazone/tirzepatide versus subjects receiving metformin/sitagliptin

    Time frame: 6 months

  2. Number of subjects failing to achieving HbA1c <6.5% Long-term

    The failure to achieving HbA1c \<6.5% (Durability) at the end of study in subjects receiving pioglitazone/tirzepatide (Group I) versus metformin/sitagliptin (Group II) in two consecutive HbA1c measurements 3 months apart.

    Time frame: month 60

Secondary outcomes

  1. Change in insulin sensitivity

    Matsuda Index of insulin sensitivity or total glucose disposal measured with the clamp.These are the gold standard methods for quantification insulin sensitivity with the OGTT or a euglycemic clamp

    Time frame: from baseline to end of study (60 months)

  2. Change in Beta Cell Function

    A calculated value using plasma glucose, insulin and C-peptide concentrations during the Oral Glucose Tolerance Test (OGTT) test.

    Time frame: Baseline to end of study (60 months)

  3. Change in body weight

    Change from study beginning to end, measured in kilograms (kg)

    Time frame: Baseline to end of study (60 months)

07

Study locations

2 of 2 sites recruiting
  • University Health System Texas Diabetic Institute
    San Antonio, Texas 78207, United States
    Recruiting
  • UT Health Science Center
    San Antonio, Texas 78229, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data will be shared with other researchers at study completion when all data are analyzed and as summary results in ClinicalTrials.gov.

Supporting information: Study protocol, Statistical analysis plan

Time frame: At study completion at the time of publication.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Apr 2029, 53 months after the start.

Of 87 non-industry phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's planned 53 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2024
First posted
Feb 7, 2024
StartActual
Nov 7, 2024
Primary completionEst.
Apr 30, 2029
CompletionEst.
Jun 30, 2029
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06246799
Responsible party
Sponsor
First posted
Feb 7, 2024
Start date
Nov 7, 2024
Primary completion
Apr 30, 2029 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Mar 10, 2026

Study contacts

Muhammad Abdul-Ghani, MD
Contact
abdulghani@uthscsa.edu
210-567-6691
Gozde Baskoy, PhD
Contact
baskoy@uthscsa.edu
210-358-7200
Muhammad Abdul-Ghani, MD
principal investigator · The University of Texas Health Science Center at San Antonio

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tirzepatide · Pioglitazone

Start the discussion